Landmark results from the Phase III PURPOSE 2 trial found that lenacapavir demonstrated 89% greater efficacy than Truvada in preventing HIV infections.
Gilead's Lenacapavir Reduces HIV Infections by 96%, Surpassing Truvada in Twice-Yearly PrEP Treatment